{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:05:52Z","timestamp":1793124352051,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2007912"],"award-info":[{"award-number":["GNT2007912"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"crossref","award":["23AARF-1020292"],"award-info":[{"award-number":["23AARF-1020292"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monitoring the progression of preclinical Alzheimer's disease (AD) is challenging due to the absence of obvious cognitive impairment, yet it's crucial for determining the optimal timing for disease-modifying treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prognostic study used data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer\u2019s Disease (A4) study. The development cohort included 412 participants from the placebo arm, and external validation was performed using 342 participants from the treatment arm. All participants had baseline brain amyloid-beta (A\u03b2) positron emission tomography (PET) standardized uptake value ratios (SUVR) below 1.4. Using the AutoScore machine learning framework, we developed two interpretable models: the AutoScore Amyloid-Beta (ASAB) model to predict A\u03b2 accumulation (&gt;\u20091.4 SUVR) and the AutoScore Phosphorylated Tau (ASPT) model to predict plasma phosphorylated tau-217 (pTau-217) elevation (&gt;\u20090.3\u00a0pg\/mL) over 4.5\u00a0years. Model performance was assessed using the area under the receiver operating characteristic curve (AUC-ROC) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ASAB model achieved an AUC-ROC of 0.87 (95% CI, 0.79\u20130.95), and the ASPT model achieved 0.86 (95% CI, 0.78\u20130.94). Modified models excluding baseline A\u03b2 SUVR or pTau-217 values maintained a strong performance (AUC-ROC 0.76\u20130.82). External validation demonstrated a robust performance, with an AUC-ROC of 0.83 (95% CI, 0.78\u20130.87) for ASAB and 0.84 (95% CI, 0.80\u20130.89) for ASPT. Key predictors included baseline biomarker levels, cholesterol, platelet count, alanine transaminase, and creatine kinase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The AutoScore-based models accurately predict longitudinal A\u03b2 and pTau-217 levels using readily available clinical and laboratory data. These interpretable tools could help clinicians and researchers monitor preclinical AD progression and identify optimal windows for intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01931-3","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T03:06:55Z","timestamp":1766113615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of an interpretable clinical scoring model to monitor the progression of preclinical Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Chenyin","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjian","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Zisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Goudey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"A4 and LEARN Study Teams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"1","key":"1931_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jalz.2013.01.013","volume":"10","author":"K Henriksen","year":"2014","unstructured":"Henriksen K, O\u2019Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, et al. The future of blood-based biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(1):115\u201331.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1931_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","volume":"13","author":"SE O'Bryant","year":"2017","unstructured":"O\u2019Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, et al. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 2017;13(1):45\u201358.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1931_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IM, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation. Lancet Neurol. 2022;21(1):66\u201377.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1931_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13041-019-0448-1","volume":"12","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer\u2019s disease. Mol Brain. 2019;12(1):26.","journal-title":"Mol Brain"},{"issue":"10","key":"1931_CR5","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/brain\/awv236","volume":"138","author":"H Braak","year":"2015","unstructured":"Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer\u2019s disease. Brain. 2015;138(10):2814\u201333.","journal-title":"Brain"},{"issue":"8","key":"1931_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw BJ, Betensky RA, Jacobs HI, Schultz AP, Sepulcre J, Becker JA, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915\u201324.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1931_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292\u2013323.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1931_CR8","doi-asserted-by":"publisher","first-page":"e14536","DOI":"10.1002\/alz.14536","volume":"21","author":"X Zhong","year":"2025","unstructured":"Zhong X, Wang Q, Yang M, Lin G, Yao K, Wu Z, et al. Plasma p-tau217 and p-tau217\/A\u03b21-42 are effective biomarkers for identifying CSF-and PET imaging-diagnosed Alzheimer\u2019s disease: Insights for research and clinical practice. Alzheimers Dement. 2025;21(2):e14536.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1931_CR9","doi-asserted-by":"publisher","first-page":"fcad057","DOI":"10.1093\/braincomms\/fcad057","volume":"5","author":"EM Jonaitis","year":"2023","unstructured":"Jonaitis EM, Janelidze S, Cody KA, Langhough R, Du L, Chin NA, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease. Brain Commun. 2023;5(2):fcad057.","journal-title":"Brain Commun"},{"issue":"5s2","key":"1931_CR10","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.1046\/j.1532-5415.5153.x","volume":"51","author":"BP Leifer","year":"2003","unstructured":"Leifer BP. Early diagnosis of Alzheimer\u2019s disease: clinical and economic benefits. J Am Geriatr Soc. 2003;51(5s2):S281\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"1931_CR11","doi-asserted-by":"crossref","unstructured":"Guest FL. Early detection and treatment of patients with Alzheimer's disease: Future perspectives. Adv Exp Med Biol. 2019;1118:295-317.","DOI":"10.1007\/978-3-030-05542-4_15"},{"issue":"10","key":"1931_CR12","doi-asserted-by":"publisher","first-page":"e21798","DOI":"10.2196\/21798","volume":"8","author":"F Xie","year":"2020","unstructured":"Xie F, Chakraborty B, Ong MEH, Goldstein BA, Liu N. AutoScore: a machine learning\u2013based automatic clinical score generator and its application to mortality prediction using electronic health records. JMIR Med Inform. 2020;8(10):e21798.","journal-title":"JMIR Med Inform"},{"key":"1931_CR13","doi-asserted-by":"crossref","unstructured":"Pan Y, Chu C, Wang Y, Wang Y, Ji G, Masters CL, Goudey B, Jin L: Development and validation of the Florey Dementia Risk Score web-based tool to screen for Alzheimer's disease in primary care. EClinicalMedicine. 2024;76.","DOI":"10.1016\/j.eclinm.2024.102834"},{"issue":"3","key":"1931_CR14","doi-asserted-by":"publisher","first-page":"e14583","DOI":"10.1002\/alz.14583","volume":"21","author":"C Chu","year":"2025","unstructured":"Chu C, Wang Y, Ma L, Mutimer CA, Ji G, Shi H, et al. PAN Y: Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity. Alzheimers Dement. 2025;21(3):e14583.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1931_CR15","doi-asserted-by":"publisher","first-page":"e2118467","DOI":"10.1001\/jamanetworkopen.2021.18467","volume":"4","author":"F Xie","year":"2021","unstructured":"Xie F, Ong MEH, Liew JNMH, Tan KBK, Ho AFW, Nadarajan GD, et al. Development and assessment of an interpretable machine learning triage tool for estimating mortality after emergency admissions. JAMA Netw Open. 2021;4(8):e2118467.","journal-title":"JAMA Netw Open"},{"key":"1931_CR16","doi-asserted-by":"crossref","unstructured":"Xie F, Liu N, Yan L, Ning Y, Lim KK, Gong C, Kwan YH, Ho AFW, Low LL, Chakraborty B: Development and validation of an interpretable machine learning scoring tool for estimating time to emergency readmissions. EClinicalMedicine 2022;45:101315.","DOI":"10.1016\/j.eclinm.2022.101315"},{"issue":"6","key":"1931_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","volume":"77","author":"RA Sperling","year":"2020","unstructured":"Sperling RA, Donohue MC, Raman R, Sun C-K, Yaari R, Holdridge K, et al. A4 Study team: Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735\u201345.","journal-title":"JAMA Neurol"},{"issue":"12","key":"1931_CR18","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med. 2023;389(12):1096\u2013107.","journal-title":"N Engl J Med"},{"issue":"4","key":"1931_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.14283\/jpad.2024.134","volume":"11","author":"RA Rissman","year":"2024","unstructured":"Rissman RA, Donohue M, Langford O, Raman R, Abdel-Latif S, Yaari R, et al. Longitudinal phospho-tau217 predicts amyloid positron emission tomography in asymptomatic Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2024;11(4):823\u201330.","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"1931_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.14283\/jpad.2024.122","volume":"11","author":"RA Sperling","year":"2024","unstructured":"Sperling RA, Donohue M, Rissman R, Johnson K, Rentz D, Grill J, et al. Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: longitudinal data from the A4 and LEARN studies. J Prev Alzheimers Dis. 2024;11(4):802\u201313.","journal-title":"J Prev Alzheimers Dis"},{"key":"1931_CR21","doi-asserted-by":"crossref","unstructured":"Collins GS, Moons KG, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, Van Smeden M: TRIPOD+ AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:3078378.","DOI":"10.1136\/bmj-2023-078378"},{"issue":"8","key":"1931_CR22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","volume":"52","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210\u20137.","journal-title":"J Nucl Med"},{"key":"1931_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3389\/fnins.2020.00745","volume":"14","author":"Y Chang","year":"2020","unstructured":"Chang Y, Li C, Yang H, Wu Y, Xu B, Zhang J, et al. 18F-florbetaben amyloid PET imaging: a Chinese study in cognitive normal controls, mild cognitive impairment, and Alzheimer\u2019s disease patients. Front Neurosci. 2020;14:745.","journal-title":"Front Neurosci"},{"issue":"1","key":"1931_CR24","doi-asserted-by":"publisher","first-page":"14690","DOI":"10.1038\/s41598-017-15001-8","volume":"7","author":"DW Kang","year":"2017","unstructured":"Kang DW, Choi WH, Jung WS, Um YH, Lee CU, Lim HK. Impact of amyloid burden on regional functional synchronization in the cognitively normal older adults. Sci Rep. 2017;7(1):14690.","journal-title":"Sci Rep"},{"key":"1931_CR25","doi-asserted-by":"crossref","unstructured":"Feizpour A, Doecke JD, Dor\u00e9 V, Krishnadas N, Huang K, Bourgeat P, Laws SM, Fowler C, Robertson J, Mackintosh L: Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform. EBioMedicine. 2024;109:105405.","DOI":"10.1016\/j.ebiom.2024.105405"},{"issue":"1","key":"1931_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, Rodr\u00edguez-Baz \u00cd, Ferrer R, Carmona-Iragui M, et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21-42 and A\u03b21-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther. 2024;16(1):139.","journal-title":"Alzheimers Res Ther"},{"key":"1931_CR27","unstructured":"Michigan Medicine Laboratories. Phospho-Tau 217, Plasma. Available at https:\/\/mlabs.umich.edu\/tests\/phospho-tau-217-plasma"},{"issue":"2","key":"1931_CR28","doi-asserted-by":"publisher","first-page":"102302","DOI":"10.1016\/j.xpro.2023.102302","volume":"4","author":"F Xie","year":"2023","unstructured":"Xie F, Ning Y, Liu M, Li S, Saffari SE, Yuan H, et al. A universal AutoScore framework to develop interpretable scoring systems for predicting common types of clinical outcomes. STAR Protoc. 2023;4(2):102302.","journal-title":"STAR Protoc"},{"key":"1931_CR29","unstructured":"Kassambara A. rstatix: Pipe-friendly framework for basic statistical tests. CRAN: Contributed packages. 2023. Available at https:\/\/rpkgs.datanovia.com\/rstatix\/."},{"key":"1931_CR30","doi-asserted-by":"crossref","unstructured":"Crosilla F, Pillirone G. Non-parametric statistics and bootstrap methods for testing the data quality of a geographic information system. In: Geodetic theory today. Berlin, Heidelberg: Springer; 1995; 14:214\u2013223.","DOI":"10.1007\/978-3-642-79824-5_30"},{"key":"1931_CR31","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00406-013-0468-2","volume":"264","author":"P Toro","year":"2014","unstructured":"Toro P, Degen C, Pierer M, Gustafson D, Schr\u00f6der J, Sch\u00f6nknecht P. Cholesterol in mild cognitive impairment and Alzheimer\u2019s disease in a birth cohort over 14 years. Eur Arch Psychiatry Clin Neurosci. 2014;264:485\u201392.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"1931_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaneurol.2013.5390","volume":"71","author":"B Reed","year":"2014","unstructured":"Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014;71(2):195\u2013200.","journal-title":"JAMA Neurol"},{"key":"1931_CR33","doi-asserted-by":"publisher","first-page":"101420","DOI":"10.1016\/j.arr.2021.101420","volume":"71","author":"MG Carbone","year":"2021","unstructured":"Carbone MG, Pagni G, Tagliarini C, Imbimbo BP, Pomara N. Can platelet activation result in increased plasma A\u03b2 levels and contribute to the pathogenesis of Alzheimer\u2019s disease? Ageing Res Rev. 2021;71:101420.","journal-title":"Ageing Res Rev"},{"issue":"7","key":"1931_CR34","doi-asserted-by":"publisher","first-page":"e197978","DOI":"10.1001\/jamanetworkopen.2019.7978","volume":"2","author":"K Nho","year":"2019","unstructured":"Nho K, Kueider-Paisley A, Ahmad S, MahmoudianDehkordi S, Arnold M, Risacher SL, et al. Association of altered liver enzymes with Alzheimer disease diagnosis, cognition, neuroimaging measures, and cerebrospinal fluid biomarkers. JAMA Netw Open. 2019;2(7):e197978.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"1931_CR35","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1002\/alz.14073","volume":"20","author":"V Devanarayan","year":"2024","unstructured":"Devanarayan V, Doherty T, Charil A, Sachdev P, Ye Y, Murali LK, et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(8):5617\u201328.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1931_CR36","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1007\/s00415-024-12631-7","volume":"271","author":"G Cecchetti","year":"2024","unstructured":"Cecchetti G, Agosta F, Rugarli G, Spinelli EG, Ghirelli A, Zavarella M, et al. Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer\u2019s disease: a real-world study. J Neurol. 2024;271(10):6739\u201349.","journal-title":"J Neurol"},{"issue":"2","key":"1931_CR37","doi-asserted-by":"publisher","first-page":"e14458","DOI":"10.1002\/alz.14458","volume":"21","author":"M Khalafi","year":"2025","unstructured":"Khalafi M, Dartora WJ, McIntire LBJ, Butler TA, Wartchow KM, Hojjati SH, et al. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer\u2019s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis. Alzheimers Dement. 2025;21(2):e14458.","journal-title":"Alzheimers Dement"},{"key":"1931_CR38","doi-asserted-by":"crossref","unstructured":"Woo MS, Therriault J, Jonaitis EM, Wilson R, Langhough RE, Rahmouni N, Benedet AL, Ashton NJ, Tissot C, Lantero-Rodriguez J: Identification of late-stage tau accumulation using plasma phospho-tau217. EBioMedicine. 2024;109:105413.","DOI":"10.1016\/j.ebiom.2024.105413"},{"issue":"5","key":"1931_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s42256-019-0048-x","volume":"1","author":"C Rudin","year":"2019","unstructured":"Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat Mach Intell. 2019;1(5):206\u201315.","journal-title":"Nat Mach Intell"},{"issue":"14","key":"1931_CR40","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJMra1814259","volume":"380","author":"A Rajkomar","year":"2019","unstructured":"Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347\u201358.","journal-title":"N Engl J Med"},{"issue":"8","key":"1931_CR41","doi-asserted-by":"publisher","first-page":"e70543","DOI":"10.1002\/alz.70543","volume":"21","author":"C Chu","year":"2025","unstructured":"Chu C, Wang Y, Ma L, Jin L, Pan Y. Development and validation of a predictive model to forecast the cerebrovascular risk burden in older people using the NACC and ROSMAP dataset. Alzheimers Dement. 2025;21(8):e70543.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1931_CR42","doi-asserted-by":"publisher","first-page":"e70057","DOI":"10.1002\/alz.70057","volume":"21","author":"C Chu","year":"2025","unstructured":"Chu C, Ma L, Wang Y, Huynh AL, Dunstan MK, Cui X, et al. Predicting severity of cerebral amyloid angiopathy neuropathology: a modeling approach using NACC and ROSMAP data. Alzheimers Dement. 2025;21(10):e70057.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01931-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01931-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01931-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:25:28Z","timestamp":1781623528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01931-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1931"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01931-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The A4 Study received approval from institutional review boards at all participating sites in the United States, Canada, Australia, and Japan. Data access was obtained through the official A4 data portal. Institutional ethics approval to analyze de-identified human data was granted by Monash University (Project ID 48297).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}